SCHEMBL1797143

SCHEMBL1797143

COC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)N(Cc1ccc(F)cc1)Cc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.44
▸ LMNA P02545 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ CCR3 P51677 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799453 0.90 POLB (0.48) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1796795 0.89 LMNA (0.45) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1798680 0.89 POLB (0.48) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1798678 0.88 MAPT (0.42) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1015454 0.81 ALDH1A1 (0.51) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1796300 0.80 ALDH1A1 (0.48) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1015136 0.80 SLC6A4 (0.51) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1795944 0.79 SERPINE1 (0.45) LMNAGAAALDH1A1CYP1A2CYP3A4
SCHEMBL7125633 0.79 ALDH1A1 (0.62) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL1015634 0.79 ALDH1A1 (0.53) MAPTLMNAGAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 MAPT 2975/4885LMNA 672/4885GAA 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback